financetom
Business
financetom
/
Business
/
--FTC to Sue Pharmacy Benefit Managers Over Insulin Prices, Wall Street Journal Reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--FTC to Sue Pharmacy Benefit Managers Over Insulin Prices, Wall Street Journal Reports
Jul 10, 2024 11:30 AM

02:03 PM EDT, 07/10/2024 (MT Newswires) --

Price: 498.71, Change: +6.59, Percent Change: +1.34

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Calibre's Valentine Gold Mine 2024 Exploration Program Underway; Shares Gained 5% On Tuesday
Calibre's Valentine Gold Mine 2024 Exploration Program Underway; Shares Gained 5% On Tuesday
Apr 3, 2024
07:10 AM EDT, 04/03/2024 (MT Newswires) -- Calibre Mining Corp. ( CXBMF ) , which gained more than 5% yesterday, on Wednesday said its 2024 exploration program at the Valentine gold mine in Newfoundland and Labrador is underway. According to a statement, the property hosts five gold deposits with measured and indicated resources of 4.0 million ounces and inferred resources...
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Apr 3, 2024
April 3 (Reuters) - Lenz Therapeutics ( LENZ ) said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study. ...
Digihost Technology Reports Loss for Q4, Revenue Grows; Provides Update
Digihost Technology Reports Loss for Q4, Revenue Grows; Provides Update
Apr 3, 2024
07:08 AM EDT, 04/03/2024 (MT Newswires) -- Digihost Technology Inc. ( DGHI ) , a US-based blockchain technology and computer infrastructure company, on Wednesday reported a fourth-quarter net loss of US$9.7 million, or US$0.34 per diluted share, as compared with a loss of US$9.7 million, or US$0.36 per diluted share, a year earlier. Revenue for the quarter ended Dec. 31,...
Cancer biotech firm Alterome Therapeutics raises $132 mln in Goldman Sachs-led round
Cancer biotech firm Alterome Therapeutics raises $132 mln in Goldman Sachs-led round
Apr 3, 2024
April 3 (Reuters) - Biotechnology firm Alterome Therapeutics said on Wednesday it has raised $132 million in a series B financing round, which was led by Goldman Sachs Alternatives. The series B financing, which brings its total funding to nearly $232 million to date, also saw participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved